Navigation Links
OrthoSynetics(TM) Donates Body Armor to New Orleans Police Department
Date:6/5/2008

Metairie-Based Company Helps to Fill Law Enforcement Need

METAIRIE, La., June 5 /PRNewswire/ -- OrthoSynetics(TM), the largest provider of business services to orthodontic and dental practices worldwide, announced today that its Community Relations Committee has donated body armor and additional state-of-the-art tactical equipment to the New Orleans Police Department.

Financial shortfalls in the wake of Hurricane Katrina have left the department in need of these supplies -- and left police officers at risk. A recent Time Magazine article ("New Orleans: Police Still Underfunded," Gilbert Cruz, 6/20/07) detailed the shortages of body armor caused by Katrina -- and the need for private donations to replace them.

"OrthoSynetics(TM) is part of the New Orleans community. Our company's employees and families live, work and play in this community, and we feel our police officers should be fully protected while they work to keep us safe," said Chris Roussos, president and CEO of OrthoSynetics(TM). "We hope this contribution helps protect our police officers, make our community stronger, and demonstrates our commitment to the New Orleans community."

Roussos, a former Army Ranger, reached out to a former colleague on behalf of OrthoSynetics(TM) to purchase the equipment from Armor Technologies(TM), a subsidiary of Diamondback Tactical, headquartered in Phoenix, Arizona.

The donated equipment includes four large Custom Armor Technologies(TM) NIJ Level 3A Concealable Body Armor, and four extra-large Custom Armor Technologies(TM) NIJ Level 3A Concealable Body Armor.

"We thank OrthoSynetics(TM) and all the company's employees for stepping up to the plate to help the police department and the community," said New Orleans Police Department Superintendent Warren J. Riley. "It is the generosity of companies like OrthoSynetics(TM) that have allowed this community to rebuild and meet the challenges of the past few years."

Orth
'/>"/>

SOURCE OrthoSynetics(TM)
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. OrthoSynetics(TM) Adds Two Experienced Pros to IT Team
2. OrthoSynetics(TM) Expands Sales Team; Prepares to Grow
3. OrthoSynetics(TM) Brings Ad Production Home to New Orleans
4. Dr. Ravi Nanda Joins OrthoSynetics(TM) as Strategic Consultant
5. Brad Williams Joins OrthoSynetics(TM) as Director, IT Infrastructure
6. OrthoSynetics(TM) Applauds SEC Suit Against Former Company Management
7. Michael Beland Named as OrthoSynetics(TM) Corporate Controller
8. Richard Drouant Joins OrthoSynetics(TM) as Graphic Designer
9. OrthoSynetics(TM) Opens Regional Offices in Dallas, Atlanta
10. Stuart Collins Joins OrthoSynetics(TM) as Director, Eastern Region Sales
11. OrthoSynetics(TM) Opens New Data Center, Colocation Facility
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 2Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Royalty Pharma Announces that Alexander von Perfall Joins Management Team 24th BTLtec Conference on 24 25 Sep in Graz Austria features Biomass to Liquids Innovators Sharing Updates on Pyrolysis and Gasification Technologies 13115 14th BTLtec Conference on 24 25 Sep in Graz Austria features Biomass to Liquids Innovators Sharing Updates on Pyrolysis and Gasification Technologies 13115 24th BTLtec Conference on 24 25 Sep in Graz Austria features Biomass to Liquids Innovators Sharing Updates on Pyrolysis and Gasification Technologies 13115 3HealthCare Partners of Nevada and Fremont Medical Center Join Forces 52190 1HealthCare Partners of Nevada and Fremont Medical Center Join Forces 52190 2Tiffany Diamond Eternity Bands and Cartier 26apos 3BLove 26apos 3B Rings 3A Beladora Announces Sharp Wedding Jewelry Sales Increase 52188 1Tiffany Diamond Eternity Bands and Cartier 26apos 3BLove 26apos 3B Rings 3A Beladora Announces Sharp Wedding Jewelry Sales Increase 52188 2Tiffany Diamond Eternity Bands and Cartier 26apos 3BLove 26apos 3B Rings 3A Beladora Announces Sharp Wedding Jewelry Sales Increase 52188 3